- Home
- POET vs IMMP Comparison
POET vs IMMP Comparison
Compare POET & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POET
- IMMP
- Stock Information
- Founded
- POET 1972
- IMMP 1987
- Country
- POET Canada
- IMMP Australia
- Employees
- POET N/A
- IMMP N/A
- Industry
- POET Semiconductors
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- POET Technology
- IMMP Health Care
- Exchange
- POET Nasdaq
- IMMP Nasdaq
- Market Cap
- POET 278.3M
- IMMP 304.0M
- IPO Year
- POET N/A
- IMMP N/A
- Fundamental
- Price
- POET $7.59
- IMMP $2.04
- Analyst Decision
- POET Strong Buy
- IMMP Buy
- Analyst Count
- POET 2
- IMMP 2
- Target Price
- POET $6.25
- IMMP $8.50
- AVG Volume (30 Days)
- POET 3.2M
- IMMP 162.0K
- Earning Date
- POET 11-14-2024
- IMMP 01-03-2025
- Dividend Yield
- POET N/A
- IMMP N/A
- EPS Growth
- POET N/A
- IMMP N/A
- EPS
- POET N/A
- IMMP N/A
- Revenue
- POET $119,946.00
- IMMP $2,563,302.00
- Revenue This Year
- POET N/A
- IMMP N/A
- Revenue Next Year
- POET $9,744.96
- IMMP $10.84
- P/E Ratio
- POET N/A
- IMMP N/A
- Revenue Growth
- POET N/A
- IMMP 9.59
- 52 Week Low
- POET $0.84
- IMMP $1.66
- 52 Week High
- POET $7.79
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- POET 78.14
- IMMP 49.23
- Support Level
- POET $4.47
- IMMP $2.00
- Resistance Level
- POET $5.34
- IMMP $2.24
- Average True Range (ATR)
- POET 0.64
- IMMP 0.13
- MACD
- POET 0.18
- IMMP -0.02
- Stochastic Oscillator
- POET 94.57
- IMMP 22.22
About POET POET Technologies Inc.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The group's operations are located in Allentown, PA, Shenzhen, China, and Singapore.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.